Last €21.54 EUR
Change Today -0.189 / -0.87%
Volume 0.0
As of 9:32 AM 12/23/14 All times are local (Market data is delayed by at least 15 minutes).

masimo corp (3M4) Snapshot

Open
€21.43
Previous Close
€21.73
Day High
€21.54
Day Low
€21.43
52 Week High
01/23/14 - €23.31
52 Week Low
05/9/14 - €15.83
Market Cap
1.1B
Average Volume 10 Days
18.0
EPS TTM
--
Shares Outstanding
52.4M
EX-Date
11/23/12
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MASIMO CORP (3M4)

masimo corp (3M4) Related Businessweek News

No Related Businessweek News Found

masimo corp (3M4) Details

Masimo Corporation, a medical technology company, develops, manufactures, and markets various noninvasive patient monitoring products worldwide. The company offers Masimo Signal Extraction Technology (SET), which provides the capabilities of measure-through motion and low perfusion pulse oximetry to address the primary limitations of conventional pulse oximetry; and Masimo rainbow SET products that monitor multiple blood measurements, including oxygen content, carboxyhemoglobin, methemoglobin, hemoglobin, pleth variability index, respiration rate, Halo Index, and In Vivo Adjustment. It develops, manufactures, and markets a family of patient monitoring solutions comprising monitors, circuit boards, sensors, and cables; Root, a patient monitoring and connectivity platform; Masimo Patient SafetyNet, a remote monitoring and clinician notification solution; and various software products. The company also provides line filters, cannulas, and mainstream adapters; and wafer epitaxy, foundry, and device fabrication services to biomedical, telecommunications, consumer products, and other markets, as well as develops and manufactures ultra-compact mainstream and sidestream capnography, and gas monitoring technologies. Masimo Corporation sells its products to hospitals, emergency medical response organizations, physician offices, veterinarians, long term care facilities, consumers, and alternate care market through its direct sales force and distributors, as well as to original equipment manufacturer partners. The company was founded in 1989 and is headquartered in Irvine, California.

3,139 Employees
Last Reported Date: 02/14/14
Founded in 1989

masimo corp (3M4) Top Compensated Officers

Founder, Chairman and Chief Executive Officer
Total Annual Compensation: $712.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $334.4K
President of Worldwide Oem Business & Corpora...
Total Annual Compensation: $335.7K
President of Worldwide Sales & Marketing and ...
Total Annual Compensation: $332.4K
Chief Information Officer
Total Annual Compensation: $329.2K
Compensation as of Fiscal Year 2013.

masimo corp (3M4) Key Developments

Masimo Announces Global Launch of Multigas Monitoring for the Root Patient Monitoring and Connectivity Platform

Masimo announced FDA 510(k) clearance and CE Mark of ISA OR+ multigas monitoring, a Masimo Open Connect (MOC-9) Module for the Root patient monitoring and connectivity platform. During general anesthesia, the ISA OR+ monitors the inhaled and exhaled concentration of five anesthetic gas agents (Sevoflurane, Isoflurane, Halothane, Desflurane, Enflurane), carbon dioxide (CO2), nitrous oxide (N2O), and oxygen (O2), in addition to respiration rate. When technology modules are connected with Root, multiple additional parameters are available including Masimo SET® pulse oximetry, noninvasive and continuous hemoglobin (SpHb), PVI, SedLine brain function monitoring, and O3 Regional Oximetry. Key features and benefits of ISA OR+ include: Requires only 50 ml sampling flow to support monitoring - Time-saving in critical situations with virtually no warm-up time and full accuracy performance in less than 20 seconds - Automatic anesthetic agent identification - Supports monitoring patients with high respiration rates, up to 150 bpm - Low-power consumption and automatic temperature and pressure compensation - Provides minimal alveolar concentration (MAC), which is calculated from the measured anesthetic agents and N2O - Appropriate for monitoring adult, pediatric, or infant patients in a range of clinical environments including the operating room and intensive care unit - Compatible with Masimo's Nomoline Adapter and the Nomoline Airway Adapter Set to interface with endotracheal tubing. O3 Regional Oximetry is FDA 510(k) pending and is not available for sale in the United States.

Masimo Announces FDA 510(K) Clearance of Radius-7(TM)

Masimo announced FDA 510(k) clearance of Radius-7(TM) for the Root(R) patient monitoring and connectivity platform, the first and only wearable, wireless monitor with Masimo's breakthrough rainbow(R) SET(R) technology, offering patients continuous monitoring with freedom of movement. With rainbow(R) SET(R) noninvasive measurements, Radius-7 with Root can alert clinicians -- at the bedside or remotely, through the Masimo Patient SafetyNet(TM) remote monitoring and notification system -- of critical changes in a patient's oxygen saturation and pulse rate -- even during states of motion and low perfusion -- as well as respiration through acoustic respiration rate (RRa(R)). Lightweight at only 0.34 lbs. (155g), the Radius-7 attaches to the patient's arm or can be placed alongside the patient in their bed, allowing untethered monitoring while they are in bed or out. With no need to disconnect and reconnect the cable to get out of bed, the Radius-7 reduces the need for nursing assistance. And the Radius-7's wireless communication functionality -- either short-range via Bluetooth back to Root or with upgradeable WiFi for long-range communication -- ensures the patient can be continuously monitored and connected to caregivers wherever they are in the hospital. Studies have shown that patient mobility is a key factor in more rapid patient recovery.(1) Radius-7 allows clinicians to continuously monitor their patients when they are mobile.

Masimo Corporation Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 01:00 PM

Masimo Corporation Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 01:00 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
3M4:GR €21.54 EUR -0.189

3M4 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CAS Medical Systems Inc $1.68 USD +0.024
Chemed Corp $106.82 USD +0.66
CONMED Corp $45.16 USD -0.17
Hutchinson Technology Inc $3.59 USD -0.01
Integra LifeSciences Holdings Corp $53.90 USD +0.22
View Industry Companies
 

Industry Analysis

3M4

Industry Average

Valuation 3M4 Industry Range
Price/Earnings 24.9x
Price/Sales 2.6x
Price/Book 4.9x
Price/Cash Flow 23.0x
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MASIMO CORP, please visit www.masimo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.